TCI Co., Ltd.
TTPEX:843699.30
TWD
-0.50
(-0.50%)
ISIN
TW0008436007
Return %
Stock
S&P 500
1Y
-12.51
14.20
3Y
-42.10
81.12
5Y
-55.07
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Quarterly Revenue
TWD
•
in mil. unless spec.Quarterly Earnings Per Share
TWD
•
in mil. unless spec.Quarterly Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Yung Hsiang Lin
- Full Time Employees
- 1,120
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- No. 187, Kang Chien Road Taipei TP Taiwan 11494
- IPO Date
- Sep 12, 2013
- Website
- tci-bio.com
- Similar Companies
- Business
- TCI Co., Ltd. (8436.TWO) operates as a contract development and manufacturing organization (CDMO) specializing in the research, development, production, and sale of functional health foods, dietary supplements, and skincare products. The company provides end-to-end services including market analysis, concept design, proprietary raw material development via Integrated Bioscience Design (IBD), formulation R&D, stability and safety testing, pilot production, and full-scale manufacturing for formats such as capsules, softgels, liquids, powders, functional beverages, snacks (jelly, bars, chocolates, gummies), facial/body/eye/lip masks, essences, sprays, creams, and gels; it also offers turnkey private-label solutions, wholesale chemical production, biotechnology R&D, and medical machinery sales. TCI serves nutraceutical and cosmetic sectors for domestic and international brands, with products distributed in Taiwan, Mainland China, the United States, North America, Europe, Asia, and over 67 countries globally. Founded in 1980 and headquartered at 8F, No. 187 Kang Chien Road, Taipei, Taiwan, TCI employs 1,120 people worldwide and maintains operations in the biotechnology and medical care industry as a TPEx-listed entity. The company targets brand owners seeking OEM/ODM services in wellness and beauty, leveraging a probiotics database of over 7,272 strains, 2,676+ patents/trademarks, and 362+ awards to deliver clinically backed, consumer-inspired innovations. In recent developments, TCI reports consolidated 2024 revenue of NT$7.24 billion, gross profit of NT$3.18 billion (44% margin), operating profit of NT$1.03 billion, and net profit of NT$974 million (EPS NT$7.60), with a proposed NT$10 per share dividend and cash reserves of NT$4.77 billion; it advances global expansion in North America, Europe, China, and Asia alongside AI-enhanced production, a new Medical Consultation Panel, and ESG initiatives including RE100 membership and 562,000 kg CO2 reduction. The company showcases liquid supplement expertise at SupplySide Global 2025, emphasizing clinically proven weight management innovations. Earlier, TCI completed a 18.4% stake acquisition in Maxigen Biotech Inc. for NT$370 million in 2021, bolstering its biotech capabilities.